№ lp_2_3_55090
File format: docx Character count: 52813 File size: 162 KB
Cyclogest is a progesterone vaginal pessary used in assisted reproductive technology cycles for luteal phase support in infertile women.
Year: 2022
Region / City: Australia
Topic: Assisted Reproductive Technology
Document Type: Pharmaceutical Submission
Organization / Institution: Gedeon Richter Australia Pty Ltd
Author: Not specified
Target Audience: Healthcare professionals, medical practitioners
Effective Period: Not specified
Approval Date: 11 February 2022
Modification Date: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Changes have been made to this item. Details of the corrigendum are at the end of this document.5.18 RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE, Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg, Ryeqo®, Gedeon Richter Australia Pty Ltd.
Year: 2024
Region / City: Australia
Subject: Endometriosis treatment
Document Type: Medical submission
Organization: Gedeon Richter Australia Pty Ltd
Author: Gedeon Richter Australia Pty Ltd
Target Audience: Medical professionals, health authorities
Period of validity: Ongoing
Approval Date: 31 January 2024
Modification Date: Not specified
Changes have been made to this item. Details of the corrigendum are at the end of this document.5.18 RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE, Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg, Ryeqo®, Gedeon Richter Australia Pty Ltd.
Year: 2024
Region / City: Australia
Subject: Endometriosis treatment
Document Type: Medical submission
Organization: Gedeon Richter Australia Pty Ltd
Author: Gedeon Richter Australia Pty Ltd
Target Audience: Medical professionals, health authorities
Period of validity: Ongoing
Approval Date: 31 January 2024
Modification Date: Not specified
Topics: Cyclogest Gedeon Richter